Zobrazeno 1 - 10
of 26
pro vyhledávání: '"H. Laharie Mineur"'
Autor:
D Molnar-Stanciu, Etienne Chatelut, H Laharie-Mineur, E Suc, N. Dohollou, L. Venat-Bouvet, C Ferrer, H. Roche, D Franck, Frédéric Pinguet, P Marquet, Sandrine Lavau-Denes, C. Massabeau, Jacques Robert, Alexandre Evrard, V Mauries, Florence Dalenc, Marc Debled, Thomas Filleron, William Jacot
Publikováno v:
Cancer Research. 78:P3-12
Background: BC is a hormone-dependent disease for 75% of pts. HT is used in both adjuvant and metastatic settings for hormone–receptor (HR) positive tumors. In adjuvant situation, a 5-year HT period at least is recommended. Side-effects (SE) freque
Autor:
Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Laurence Venat-Bouvet, Laurent Cany, Stéphanie Catala, David Khayat, Laetitia Gambotti, Iris Pauporté, Celine Faure-Mercier, Sophie Paget-Bailly, Julie Henriques, Jean Marie Grouin, C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, JL Bréau, AK Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, JL Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, AF Dillies, X Durando, JP Ferrière, C Mouret-Reynier, JM Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, AC Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, JP Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, JM Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, JM Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, JC Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, G Sadki-Benaoudia, A Marti, AL Villing, B Slama, JL Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, MJ Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, JC Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, JF Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, JF Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, P Nouyrigat, S Clippe, MC Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, D Fric, C Garnier, C Leyronnas, T Kreitman, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, JF Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, JP Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, JC Legueul, J Mandet, D Besson, AC Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, JM Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, CB Levaché, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, GA Baumont, M Bégue, S Gréget, JL Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, JL Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, JP Chantelard, GA L'Helgoualc'h, EC Antoine, A Kanoui, JF Llory, JM Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, N Barbet, N Dohollou, K Yakendji
Publikováno v:
Lancet (London, England). 393(10191)
Summary Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned fin
Autor:
W. Lescaut, Anne Floquet, C.B. Levaché, C. Garnier Tixidre, Dominique Berton-Rigaud, E. Malaurie, Frédéric Selle, H. Barletta, D. Mollon-Grange, Olivier Tredan, Eric Pujade-Lauraine, Philippe Follana, Catherine Delbaldo, Rémy Largillier, M-C. Kaminsky-Forrett, Jérôme Alexandre, A.M. Savoye, H. Laharie-Mineur, C. Bosacki, Agnès Dechartres
Publikováno v:
Annals of Oncology. 30:v418
Background Bevacizumab (bev) is approved in Europe (EU) for first line therapy of OC patients (pts). This study aimed to evaluate the use of Bev in real life, with a focus on toxicity. Methods Representative centers in France of French regions and of
Autor:
Daniel Serin, S. Ellis, Z. Douadi-Gaci, I Latorzeff, C Marchal, La Lande B De, C. Lemanski, M. Leblanc-Onfroy, I. Lecouillard, D. Cowen, J. Cretin, P. Bontemps, H. Laharie-Mineur, Olivier Pradier, D. Azria, P. Lagarde, Séverine Racadot, Céline Bourgier, A. Benyoucef, Christelle Levy, K Peignaux
Publikováno v:
Cancer Research. 71:OT2-06
Background Ductal carcinoma in situ is defined as breast cancer confined to the ducts of the breast without evidence of penetration of the basement membrane. Local treatment quality represents one of the most prognostic factors as half of recurrences
Autor:
H. Laharie Mineur, Laurent Miglianico, O. Bouche, Julien Taieb, Emilie Barbier, Laetitia Dahan, E. Francois, A. Gratet, Y. Rinaldi, Côme Lepage, F. Khemissa Akouz, David Malka, Caroline Petorin, C. Rebischung, J.M. Phelip
Publikováno v:
Annals of Oncology. 29:viii244
Autor:
P. Regnault de la Mothe, F. Amestoy, V. Vendrely, N. Bonichon-Lamichhane, M. Antoine, F. Lipinski, A. Petit, B. Henriques, C. Genebes, C. Debelleix, D. Celerier, H. Laharie-Mineur, A. Blouet
Publikováno v:
Cancer/Radiothérapie. 22:718
Objectif de l’etude Analyse des sites de recidives du cancer du canal anal apres chimioradiotherapie conformationnelle avec modulation d’intensite (RCMI). Materiel et methode Entre septembre 2007 et decembre 2016, 254 patients ont ete pris en cha
Autor:
Moïse Namer, Joseph Gligorov, Mahmut Ozsahin, H. Laharie-Mineur, Eric-Charles Antoine, B. De Lafontan, Bruno Cutuli, Hugo Marsiglia, L. Aimard, Yazid Belkacemi, David Azria
Publikováno v:
Annals of Oncology : Official Journal of the European Society For Medical Oncology, vol. 19, no. 6, pp. 1110-1116
BACKGROUND: Trastuzumab (T) combined with chemotherapy has been recently shown to improve outcome in HER2-positive breast cancer (BC). The aim of this study was to evaluate the toxic effects of concurrent radiation therapy (RT) and T administration i
Autor:
G André, F. Valentin, Marie-Hélène Dilhuydy, L. Mauriac, H. Laharie-Mineur, B. Barreau, A. Avril, C. Tunon-de-Lara, M. Durand, S. Mathoulin, J. M. Dilhuydy, Marc Debled, J.-E. Bussieres, Gaëtan MacGrogan
Publikováno v:
Journal de Gynécologie Obstétrique et Biologie de la Reproduction. 36:260-266
Resume Objectifs Etudier, retrospectivement des carcinomes canalaires in situ (CCIS) bilateraux, traites a l'institut Bergonie et rechercher la relation entre les deux evenements. Materiel et methodes De 1971 a 2001, sur 812 patientes prises en charg
Publikováno v:
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 11(5)
Trastuzumab (Herceptin) is the first humanised monoclonal antibody targeting the HER2 antigen in breast cancer. HER2 receptor has been individualised 20 years ago. During the past 10 years, trastuzumab administration has radically modified the progno
Autor:
G, André, C, Tunon-de-Lara, G, Macgrogan, H, Laharie-Mineur, J-E, Bussieres, F, Valentin, B, Barreau, M-H, Dilhuydy, J-M, Dilhuydy, L, Mauriac, M, Debled, M, Durand, S, Mathoulin, A, Avril
Publikováno v:
Journal de gynecologie, obstetrique et biologie de la reproduction. 36(3)
In a retrospective study of bilateral Ductal Carcinoma In Situ (DCIS), cases were analysed to determine the relationship between the two events.From 1971 to 2001, among 812 patients with DCIS in Bergonie Institute, 78 suffering from bilateral DCIS an